Norwich forming Indian CRO to support Alvogen & clients

By Nick Taylor

- Last updated on GMT

Related tags: Clinical trial, Pharmacology, Contract research organization

Norwich Pharmaceuticals is expanding beyond its traditional manufacturing focus by launching a CRO in India to provide clients, and its parent company Alvogen, with clinical research services.

Generics manufacturer Alvogen is investing in the contract research organisation (CRO) to support its own activities and generate additional revenues through the Indian clinical trial sector.

Norwich Clinical Services is setting up in Bangalore, India and will initially offer pharmacovigilance monitoring, bioanalytical studies and medical writing services. Later this year its offering will expand into Phase I to IV studies when a 60-bed clinical trial facility opens.

The facility is equipped to conduct pharmacokinetics in healthy volunteers, drug metabolism studies, bioavailability and bioequivalence work, dose proportionality trials and multiple dose investigations.

To support these activities Norwich has appointed people with experience of clinical research and the Indian market. Between them the team has completed more than 50 clinical trial programmes and 2,000 bioanalytical studies.

Alvogen predicts the CRO will employ 100 people within its first year of operation. Doug Drysdale, CEO of Alvogen, added that the CRO “will be a pivotal component to growing our business as we continue to expand capabilities to meet the demands associated with new markets​”.

Expansion strategy

In addition to the CRO, Alvogen is setting up an active pharmaceutical ingredient (API) sourcing office in Bangalore. This will operate under the Alvogen name and help the company strengthen its relationships with Indian suppliers of raw materials.

For Norwich the CRO represents the latest step in a period of expansion. Earlier steps include investment in a pilot scale plant and addition of potent compound development capabilities.

Together these expansions represent a strategic shift to broaden the company’s offering, beyond its traditional focus on commercial manufacturing and packaging, to allow it to support clients throughout the lifecycle of a product.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us


View more